[ad_1] Alexion Pharmaceuticals Inc. ALXN, + 0.37% Wednesday announced an agreement to purchase Syntimmune for a total value of $ 1.2 billion. Syntimmune is a clinical stage biotechnology company that is currently …
Read More »Alexion Pharmaceuticals buys Syntimmune for up to $ 1.2 billion, including potential milestone payments
